Good manufacturing practice and viral safety.
The concept of virus inactivation during the manufacture of blood products raises questions about possible recontamination of the product by the environment. A strict regime of good manufacturing practice (GMP) is mandatory. The guidelines originally issued by the World Health Organization (WHO), and now law in most countries, are an excellent basis for the operation of a production plant. The following elements of GMP require special concern: (i) All functions shall be defined in a clear organization chart. (ii) Personnel shall be appropriately trained for the job and to perfect hygiene. (iii) Buildings and facilities, as well as supply systems, shall exclude the possibility of recontamination of already virus-inactivated materials. (iv) Equipment shall be easy to clean and fully sterilizable. (v) Production shall follow appropriate written procedures. (vi) The Quality Control Organization shall monitor the process by in-process controls and review the records for possible deviations. All GMP issues are coordinated by a Quality Assurance Organization that also reviews the overall performance of the operation. The maintenance of viral safety of the products basically depends upon the full commitment of all bodies involved to proper and non-negotiable GMP.
D000998:Antiviral Agents; D001771:Blood Banks / Q000331:legislation & jurisprudence*; D005591:Chemical Fractionation; D004340:Drug Contamination; D004345:Drug Industry / Q000331:legislation & jurisprudence*; D017408:Guidelines as Topic; D011785:Quality Assurance, Health Care; D014777:Virus Diseases / Q000635:transmission*; D014944:World Health Organization
D000998:Antiviral Agents